Because large studies did not show robust, reproducible weightloss outcomes, development as a formal obesity drug was discontinued, and AOD9604 today is typically used offlabel as a wellness or bodycomposition adjunct rather than an FDAapproved obesity medication
Because only a small share of patients with high B12 are found to have cancer, the value does not function as a standalone screening test
So, what happens when your B12 levels dip a little low
Compounding and the FDA: questions and answers
We dont just customize therapies for men and women, we tailor treatment for each individual carefully
Any assertion to the contrary is not supported by evidence It IS fair to say that there is no clear evidence of harm in a relatively data free zone in humans, and that there is a plausible argument for benefit based upon in vitro and animal studies as well as mechanism of action - particularly with BPC